Broadcasting precision therapies for universal reach
Lofty goals need innovative solutions. That’s where Stereo comes in.
Target specificity and heterogeneity are substantial challenges in many diseases, but especially in solid tumors where many patients are still left without any good treatment options.
At Stereo Bio we are pioneering novel solutions for these patients with a targeted multi-specific approach. We are focused on pMHC targets, which are exquisitely specific to a cell of interest with minimal expression elsewhere in the body. By taking a multi-specific approach to these targets, we are also tackling heterogeneity, offering broader tumor coverage and expanding the number of patients with the potential to benefit from our innovative solutions.
Science
We are building a purpose-built solution to the limiting issues of a narrow therapeutic window and target heterogeneity.
To begin, we are leveraging the success of T-cell engagers to harness the immune system to attack difficult to treat tumors, already shown to be effective against pMHC targets. The novelty and power in our molecules lie in the binding element: the Tracker, a small soluble subunit of the TCR. Trackers make use of the natural biological relationship between pMHCs and T-cell receptors to encourage proper binding and drive T-cells to kill cancer cells while also providing the potential for antibody-like developability.
Platform
Stereo’s Broadcast platform builds the ideal multi-specific molecules for hard-to-treat heterogeneous tumors.
We have built a proprietary tool for identifying the most impactful pairs of targets and from there we can discover novel Trackers, optimize them for drug-like properties, and identify the best multi-specific formats for efficient T-cell killing. Every element of our platform is designed to broaden both tumor coverage as well as the number of patients with the potential to respond to our treatments.
Pipeline
Our first programs are focused on tackling heterogeneous tumors using a combination of targets aimed at maximizing tumor coverage and increasing patient access. Subsequent programs are being explored in oncology as well as in other indication areas where specificity and heterogeneity are tricky problems, such as autoimmune diseases.
| Program |
Target Identification
Target ID
Discovery
Lead Optimization
Lead Opt
Pre-Clinical
|
|---|---|
|
Program 1
Solid Tumor Indications
|
|
|
Program 2
Solid Tumor Indications
|
|
|
Program 3
|
|
|
Program 4
|